Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on PDS Biotechnology (PDSB – Research Report). The associated price target remains the same with $21.00.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding PDS Biotechnology’s promising developments. The initiation of the Phase 3 VERSATILE-003 trial marks a significant milestone for the company, as it evaluates the safety and efficacy of their Versamune HPV therapy in combination with pembrolizumab for treating HPV16-positive head and neck squamous cell carcinoma. This trial is pivotal, enrolling approximately 350 patients and focusing on overall survival as the primary endpoint, with secondary endpoints including objective response rate and progression-free survival.
Furthermore, the strong scientific and clinical foundation supporting VERSATILE-003, alongside the positive outcomes from the previous Phase 2 VERSATILE-002 study, bolster confidence in the potential success of the therapy. The earlier trial demonstrated clear clinical benefits, particularly in terms of response rates and survival metrics, which de-risk the late-stage development of Versamune HPV. These factors collectively suggest that the therapy could become the first HPV-targeted immunotherapy for this type of cancer, justifying the Buy rating.
Questions or Comments about the article? Write to editor@tipranks.com